COVID-19

Tonix Pharmaceuticals Announces Initiation of Enrollment in the MGH Phase 2 ‘POWER’ Study of TNX-1900 (Intranasal Potentiated Oxytocin) for the Treatment of Pediatric Obesity

Preliminary Data Suggest that Oxytocin May Simultaneously Reduce Energy Intake and Increase Energy Expenditure TNX-1900 (Intranasal Potentiated Oxytocin) May Serve…

1 year ago

EyePoint Pharmaceuticals Announces Chief Executive Officer Transition

– Jay S. Duker, M.D., Previously President and Chief Operating Officer, Appointed President and Chief Executive Officer – – Nancy S.…

1 year ago

Tango Therapeutics Announces First Patient Dosed in TNG462 Phase 1/2 Trial in Patients With MTAP-deleted Solid Tumors

BOSTON, July 10, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering the…

1 year ago

CancerVAX CEO Ryan Davies Discusses Biotech Entrepreneurship with Pyxis Oncology CEO Dr. Lara Sullivan

The two industry leaders focus on navigating the biotech industry and immuno-oncology researchLEHI, Utah, July 10, 2023 (GLOBE NEWSWIRE) --…

1 year ago

Nicox Estimates Potential Annual Global Net Sales for NCX 470 of over $300 million

Press ReleaseNicox Estimates Potential Annual Global Net Sales for NCX 470 of over $300 millionNCX 470 therapeutic profile positively received…

1 year ago

Xtant Medical Announces Closing of $15 Million Private Placement

BELGRADE, Mont., July 07, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company…

1 year ago

Axsome Therapeutics Initiates FOCUS Phase 3 Trial of Solriamfetol for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults

NEW YORK, July 07, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel…

1 year ago

Late-Breaking KidneyIntelX Evidence Released at 83rd American Diabetes Association Scientific Sessions

12 Months KidneyIntelX™ in vitro prognostic testing continued to demonstrate clinical actions that lead to improvement in both diabetes (A1C…

1 year ago

FDA Grants Traditional Approval for LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease

The first and only approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional…

1 year ago

Hillstream BioPharma Licenses Technology to Develop Proprietary HER2 and HER3 Antibody Drug Conjugates against Drug-Resistant Breast, Lung, Gastric, and Ovarian Cancers

Anti-HER2 and Anti-HER3 monoclonal antibodies designed to have a high drug-to-antibody ratio intended enhance the bystander killing effect and be…

1 year ago